

Fingolimod 0.5 mg

Physician's Checklist

Important Information to remember
about Golifa (fingolimod) treatment

Objectives

This Physician Checklist is essential to ensure the safe and effective use of Golifa® (fingolimod) and for the appropriate management of important safety risks. Please be advised to carefully read before prescribing, dispensing, and administering the product

Considerations in (Fingolimod) Patient Selection

-Fingolimod is suitable for adult and pediatric patients (≥10 years old) for the treatment of highly active relapsing remitting MS (RRMS)*. While many patients may be suitable for treatment, the following section highlights patients in whom Fingolimod is contraindicated or not recommended.

Considerations for treatment initiation

-Fingolimod causes transient heart rate reduction and may cause atrioventricular (AV) conduction delays following initiation of treatment. All patients should be monitored for a minimum of 6 hours on treatment initiation. Below is a brief overview of monitoring requirements. Refer to page 4 for more information.

Appropriate

-Eligible adult and pediatric patients (≥10 years old) with highly active RRMS who have not responded to a full and adequate course of at least one disease modifying therapy or those with rapidly evolving, severe RRMS*.

Contraindications

-Known immunodeficiency syndrome, patients with increased risk for opportunistic infections (including immunocompromised patients), severe active infections, active chronic infections, known active malignancies, severe liver impairment, severe cardiac arrhythmias requiring anti arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs, patients with second degree Mobitz type II AV block or third- degree AV block, or sick-sinus syndrome (if they do not wear a pacemaker), patients with a baseline QTc interval of ≥500 msec, patients who in the previous 6 months had myocardial infarction, unstable angina, stroke/transient ischemic attack, decompensated heart failure, or New York Heart Association class III/IV heart failure, pregnant women, women of child-bearing potential (WOCBP including female adolescents) not using effective contraception, and patients with hypersensitivity to the active substance or to any of the excipients.

Summary of Recommendations

Important Information to remember
about Golifa (fingolimod) treatment

Fingolimod 0.5 mg

Not recommended

Consider only after performing risk/benefit analysis and consulting a cardiologist

Sino-atrial heart block, history of symptomatic bradycardia or recurrent syncope, significant QT-interval prolongation[†], history of cardiac arrest, uncontrolled hypertension or severe sleep apnea.



At least overnight extended monitoring is recommended. Consult cardiologist regarding appropriate first-dose monitoring.

Taking beta-blockers, heart rate lowering calcium channel blockers[‡], or other substances that are known to lower the heart rate[§].



Consult cardiologist regarding possibility of switching to nonheart- rate-lowering drugs. If change in medication is not possible, extend monitoring to at least overnight.

-Fingolimod is indicated as a single disease-modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and pediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy, or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.[†]QTc >470 msec (adult females), >460 msec (pediatric females), or >450 msec (adult and pediatric males).

[†]Includes verapamil or diltiazem. [§]Includes Class Ia and Class III antiarrhythmics, ivabradine, digoxin, anticholinesteratic agents, or pilocarpine.

Summary of Recommendations

Important Information to remember
about Golifa (fingolimod) treatment

Fingolimod 0.5 mg

PHYSICIAN'S CHECKLIST: Recommended steps to managing patients on Fingolimod

- The checklist and schematic that follow are intended to assist in the management of patients on Fingolimod.
- Key steps and considerations while starting, continuing, or discontinuing treatment are provided.

Prior to initiating treatment

- ☐ Ensure patients are not concomitantly taking Class Ia or Class III antiarrhythmic medicines.
- ☐ Conduct baseline electrocardiogram (ECG) and blood pressure (BP) measurement.
- ☐ Treatment with Fingolimod is not recommended in the following patients, unless anticipated benefits outweigh the potential risks:
Those with sino-atrial heart block, history of symptomatic bradycardia or recurrent syncope, significant QT-interval prolongation*, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnea.
- ☐ Seek advice from a cardiologist regarding the most appropriate monitoring at treatment initiation; at least overnight extended monitoring is recommended.
Those receiving concurrent therapy with beta- blockers, heart-rate-lowering calcium channel blockers (e.g. verapamil or diltiazem), or other substances which may decrease heart rate (e.g. ivabradine, digoxin, anticholinesteratic agents, or pilocarpine).
- ☐ Seek advice from a cardiologist regarding a switch to non-heart-rate-lowering medicinal products prior to initiation of treatment.
- ☐ If heart-rate-lowering medication cannot be stopped, seek advice from a cardiologist regarding the most appropriate monitoring at treatment initiation; at least overnight extended monitoring is recommended.
- ☐ For pediatric patients, assess Tanner staging, measure height and weight, and consider a complete vaccination schedule, as per standard of care.
- ☐ Avoid co-administration of anti-neoplastic, immunomodulatory, or immunosuppressive therapies due to the risk of additive immune system effects. For the same reason, a decision to use prolonged concomitant treatment with corticosteroids should be taken after careful consideration.
- ☐ Obtain recent (within 6 months) transaminase, and bilirubin levels.

Summary of Recommendations

Important Information to remember
about Golifa (fingolimod) treatment

Fingolimod 0.5 mg

Prior to initiating treatment

- ☐ Obtain recent (within 6 months or after discontinuation of prior therapy) full blood count.
- ☐ Inform WOCBP that fingolimod is contraindicated in pregnant women and WOCBP not using effective contraception.
- ☐ Fingolimod is teratogenic. Confirm a negative pregnancy test result in WOCBP prior to starting treatment and repeat at suitable intervals during treatment.
- ☐ Inform WOCBP about the serious risks of Fingolimod to the fetus.
- ☐ Provide all patients, parents (or legal representatives) and caregivers with the Pregnancy-Specific Patient Reminder Card.
- ☐ Counsel WOCBP (including female adolescents and their parents/caregivers) to avoid pregnancy and use effective contraception both during treatment and for 2 months after treatment discontinuation. Counseling should be facilitated by the Pregnancy-Specific Patient Reminder Card.
- ☐ Delay initiation of treatment in patients with severe active infection until resolved.
- ☐ Human papilloma virus (HPV) infection, including papilloma, dysplasia, warts, and HPV-related cancer, has been reported in the post-marketing setting. Cancer screening (including a Pap test), and vaccination for HPV-related cancer is recommended for patients as per standard of care.
- ☐ Check varicella zoster virus (VZV) antibody status in patients without a healthcare professional confirmed history of chickenpox or documentation of a full course of varicella vaccination. If negative, a full course of vaccination with varicella vaccine is recommended and treatment initiation should be delayed for 1 month to allow full effect of vaccination to occur.
- ☐ Conduct an ophthalmologic evaluation in patients with history of uveitis or diabetes mellitus.
- ☐ Conduct a dermatologic examination. The patient should be referred to a dermatologist in case suspicious lesions, potentially indicative of basal cell carcinoma, or other cutaneous neoplasms (including malignant melanoma, squamous cell carcinoma, Kaposi's sarcoma and Merkel cell carcinoma), are detected
- ☐ Provide patients, parents and caregivers with the Patients, Parent's and Caregiver's Guide.

Summary of Recommendations

Important Information to remember
about Golifa (fingolimod) treatment

Fingolimod 0.5 mg

Treatment initiation algorithm

All patients, including pediatric patients, need to be monitored for at least 6 hours during treatment initiation, as described in the algorithm below.

This procedure should also be followed in pediatric patients when the dosage is switched from 0.25 mg to 0.5 mg Fingolimod once daily*

It should also be followed at re-initiation of treatment if Fingolimod is discontinued for:

- One day or longer within the first 2 weeks of treatment
- More than 7 days during weeks 3 and 4
- More than 2 weeks after the first month of treatment

In addition, for patients in whom Fingolimod is not recommended, advice should be sought from a cardiologist regarding appropriate monitoring; at least overnight monitoring is recommended for this group.

Monitor for a minimum of 6 hours

- Perform baseline ECG and BP measurement.
- Monitor for a minimum of 6 hours for signs and symptoms of bradycardia, with hourly pulse and BP checks. If patient is symptomatic, continue monitoring until resolution Continuous (real-time) ECG is recommended throughout the 6-hour period.
- Perform ECG at 6 hours.

Summary of Recommendations

Important Information to remember
about Golifa (fingolimod) treatment

Fingolimod 0.5 mg

Did the patient require
pharmacologic intervention at
any time during the monitoring
period?



Monitor overnight in a medical
facility. The first-dose monitoring
should be repeated after the
second dose of Fingolimod.



Did third-degree AV block occur
at any time during the monitoring
period?



Extend monitoring at least
overnight, until the findings have
resolved.



At the end of the monitoring peri-
od, have any of the following crite-
ria been met?

- HR <45 bpm, <55 bpm in
pediatric patients aged ≥12 years
old, or <60 bpm in pediatric
patients aged 10 to <12 years of
age.
- ECG shows new-onset
second-degree or higher AV block
or QTc interval ≥500 msec



Extend monitoring at least
overnight, until the findings have
resolved.



At the end of the monitoring
period, is the HR the lowest since
the first dose was administered?



Extend monitoring by at least 2
hours and until the heart rate
increases.



First-dose monitoring is complete

BP=blood pressure; ECG=electrocardiogram;
HR=heart rate;
QTc=heart-rate-corrected QT interval.
*For pediatric patients (≥10 years old), the
approved dosing for Fingolimod is
0.25 mg once daily for patients weighing ≤40 kg,
and 0.5 mg once daily for
patients weighing >40 kg.



The above first-dose monitoring procedure should
also be followed at reinitiation of treatment if
fingolimod therapy is discontinued for:

- One day or longer within the first 2 weeks of
treatment
- More than 7 days during weeks 3 and 4
- More than 2 weeks after the first month of
treatment of treatment

Summary of Recommendations

Important Information to remember
about Golifa (fingolimod) treatment

Fingolimod 0.5 mg

During treatment

- A full ophthalmologic assessment should be considered:
 - 3–4 months after starting treatment for the early detection of visual impairment due to drug-induced macular edema.
 - During treatment in patients with diabetes mellitus or with a history of uveitis.
- Counsel patients to report signs and symptoms of infection immediately to their prescriber during, and for up to 2 months after, treatment.
 - Perform prompt diagnostic evaluation in patients with symptoms and signs consistent with encephalitis, meningitis or meningoencephalitis and initiate appropriate treatment if diagnosed.
- Serious, life-threatening, and sometimes fatal cases of encephalitis, meningitis or meningoencephalitis caused by herpes simplex virus (HSV) and VZV were reported while on Fingolimod treatment.
- Reports of cryptococcal meningitis (sometimes fatal) have been received after approximately 2–3 years of treatment, although an exact relationship with the duration of treatment is unknown.
- Be vigilant for clinical symptoms or MRI findings suggestive of progressive multifocal leukoencephalopathy (PML). If PML is suspected, treatment with Fingolimod should be suspended until PML has been excluded.
- Cases of PML have occurred after approximately 2–3 years of monotherapy treatment although an exact relationship with the duration of treatment is unknown.
- Suspend treatment during serious infections.
- Check full blood count periodically during treatment, at month 3 and at least yearly thereafter, until 2 months after treatment discontinuation and interrupt treatment if lymphocyte count is confirmed as $<0.2 \times 10^9/L^*$.
- Check liver transaminases and serum bilirubin before starting treatment and at months 1, 3, 6, 9, and 12 on therapy and periodically thereafter until 2 months after Fingolimod discontinuation or at any time there are signs or symptoms of hepatic dysfunction.
 - Some cases of acute liver failure requiring liver transplant and clinically significant liver injury have been reported.

Summary of Recommendations

Important Information to remember
about Golifa (fingolimod) treatment

Fingolimod 0.5 mg

During treatment

• In the absence of clinical symptoms, if liver transaminases are: – Greater than 3 times the upper limit of normal (ULN) but less than 5 times ULN without increase in serum bilirubin, more frequent monitoring including serum bilirubin and alkaline phosphatase (ALP) measurement should be instituted to determine if further increases occur and in order to discern if an alternative aetiology of hepatic dysfunction is present. – If liver transaminases are. – At least 5 times the ULN or at least 3 times the ULN associated with any increase in serum bilirubin, fingolimod should be discontinued. Hepatic monitoring should be continued if serum levels return to normal, if an alternative cause of the hepatic dysfunction is discovered, Fingolimod may be restarted based on a careful benefit- risk assessment of the patient. • In case of presence of clinical symptoms suggestive of hepatic dysfunction, the Liver enzymes and bilirubin should be checked immediately and fingolimod should be discontinued if significant liver injury is confirmed. – While on treatment, women should not become pregnant. Discontinue treatment if a woman becomes pregnant. Fingolimod should be stopped 2 months before planning a pregnancy, and the possible return of disease activity should be considered. An ultrasonography examination should be performed and medical advice about the harmful effects of Fingolimod to the fetus should be provided.

- Advise WOCBP that effective contraception must be used during treatment and for at least 2 months after treatment discontinuation. Pregnancy tests must be repeated at suitable intervals.

- WOCBP (including female adolescents and their parents/legal representatives/caregivers) must be informed regularly about the serious risks of Fingolimod to the fetus.

- Ensure WOCBP (including female adolescents), their parents (or legal representatives), and caregivers receive regular counseling facilitated by the Pregnancy-Specific Patient Reminder Card.

- Vigilance for basal cell carcinoma and other cutaneous neoplasms is recommended with Skin examination every 6 to 12 months. and referral to a dermatologist if suspicious lesions are detected.

• Caution patients against exposure to sunlight without protection.

• Ensure patients are not receiving concomitant phototherapy with UV-B-radiation or PUVA-chemotherapy.

- Fingolimod has an immunosuppressive effect and can increase the risk of developing lymphomas (including mycosis fungoides), and other malignancies (particularly those of the skin), and serious opportunistic infections. Surveillance should include vigilance for both skin malignancies and mycosis fungoides. Closely monitor patients during treatment, especially those with concurrent conditions, or known factors, such as previous immunosuppressive therapy; and discontinue treatment if a risk is suspected.

- Cases of seizure, including status epilepticus, have been reported. Vigilance for seizures, especially in those patients with underlying conditions or with a pre-existing history or family history of epilepsy, is recommended.

- Monitor pediatric patients for signs and symptoms of depression and anxiety.

- Reassess on an annual basis the benefit of Fingolimod treatment versus risk in each patient, especially pediatric patients.

***Approved dose of 0.5 mg once daily (or 0.25 mg once daily in pediatric patients ≥ 10 years old] with a body weight of ≤ 40 kg) to be used when restarting treatment as other dosing regimens have not been approved.**

Summary of Recommendations

Important Information to remember
about Golifa (fingolimod) treatment

Fingolimod 0.5 mg

After treatment discontinuation

- Repeat first-dose monitoring as for treatment initiation when treatment is interrupted for:
 - One day or more during the first 2 weeks of treatment.
 - More than 7 days during weeks 3 and 4 of treatment.
 - More than 2 weeks after one month of treatment.
- Counsel patients to report signs and symptoms of infection immediately to their prescriber for up to 2 months after discontinuation.
- Instruct patients to be vigilant for signs of encephalitis, meningitis, or meningoencephalitis infection and PML.
- Inform WOCBP (including female adolescents and their parents/caregivers) that effective contraception is needed for 2 months after discontinuation because of the serious risks of Fingolimod to the fetus.
- Advise women who stop treatment with Fingolimod because they are planning a pregnancy that their disease activity may return.
- Vigilance for the possibility of severe exacerbation of disease following discontinuation of treatment is recommended.
- In cases of severe exacerbation appropriate treatment should be initiated as required.

Summary guidance specifically for pediatric patients

- Consider a complete vaccination schedule before starting Fingolimod.
- Counsel patients and their parents/caregivers on Fingolimod's immunosuppressive effects.
- Assess physical development (Tanner staging), and measure height and weight, as per standard of care.
- Perform cardiovascular monitoring.
- Perform first-dose monitoring on treatment initiation due to the risk of bradyarrhythmia.
- Repeat first-dose monitoring in pediatric patients when the dosage is switched from 0.25 mg to 0.5 mg Fingolimod once daily*.
- Emphasize the importance of treatment compliance to patients, especially with regard to treatment interruption and the need to repeat first-dose monitoring.
- Monitor the patient for signs and symptoms of depression and anxiety.
- Provide guidance on seizure monitoring.
- Provide pregnancy specific guidance including the Pregnancy specific patient reminder card to female adolescent patients of childbearing potential and their parents/caregivers*.

*For pediatric patients (≥ 10 years old), the approved dosing for Fingolimod is 0.25 mg once daily for patients weighing ≤ 40 kg, and 0.5 mg once daily for patients weighing >40 kg.

Refer to SPC or PIL for further information.

Summary of Recommendations

Important Information to remember
about Golifa (fingolimod) treatment

Fingolimod 0.5 mg

For report adverse events:

Saudi Food and Drug Authority

The National Pharmacovigilance and Drug Safety Centre

SFDA call center: 19999

E-mail: npc.drug@sfdagov.sa

Website: <https://ade.sfdagov.sa>



OR

Marketing Authorization Holder:

Middle East Pharmaceutical Industries Co. Ltd.
(Avalon Pharma)

Riyadh, Kingdom of Saudi Arabia

Mobile: +966 55 222 1704

E-mail: pharmacovigilance@avalon.com.sa

Website: <https://avalonpharmaceutical.com>

-By reporting side effects, you will help provide more
information about the medicine's safety

* For extra copies, please contact: pharmacovigilance@avalon.com.sa

Version Number: 01

SFDA agreement date: 08/2024

This document is approved by the Executive Directorate of e'S Pharmacovigilance at SFDA,